Replies to post #10708 on BioCurex, Inc.(fka BOCX)

[opportunityknocking]

Bottom line is we will all be rewarded. The technology is beyond anything else in biomarker discovery. I sense the next wave of news will reassure everyone that we were all right to hang in there. Everyone knows how I feel about management's previous press releases and I can only hope we don't see more paid dilutive hype and we get the deserved real media attention. The news should be great, but learn from your mistakes and take the high road this time. All you are creating by paying for media coverage is an opportuntity for a quick trade. We need long term investors that share our vision. This has never been a short term trade for me as evidenced by the fact I have been adding to my position over a 4 year period. I am concerned that if Wittenberg continues this route of paying for hype all momentum will be lost to day traders. Let's get the backing of all governments with socialized medicine. We can save lives and it makes economic sense. Many of the Fortune 500 companies are there because of governmental contracts. Think bigtime and we will be bigtime.

[mata hari]

Attn: bocxholders. Our MANIPULATING/shorting entity is working it hard. Remember these guy(s)/gal(s) have built a large short position over the past several years-he/she/it/they has/have accounts at one or more prime trading desks. He/she/it/they MANIPULATE this stock with scam trading-you know that algorithmic modeling that eventually ate Wall Street.

I’ve reread that financial blog post from late October. Really strange that this guy didn’t even mention the upcoming stock offering-not very good dew diligence now is it…it’s as if this cut and past blog was just to quickly pump up the stock for some short seller to let’er rip. Certainly bocx or smithline is not responsible for this guy—it’s a quiet period: SEC would have a field day if bocx or smithline were involved-there would be no registration for the stock offering.

Someone compares recaf to makers of growth factors and vascular growth-recaf is different.

Invereness signed a semi-exclusive license for an automated use. Someone claims this was for inverness’s semi-automatic elisa machines. Not the case. When inverness signed the license agreement, there was doubt if recaf could be used in an elisa format. Any speculation that inverness is not working on multiple platforms for recaf is…well speculation. Bocx has reported that inverness is manufacturing recaf—this is huge. Part of any successful clinical trial is the certification of the manufacturing facilities and methods.

Abbott and inverness have a very significant shared history. Abbott diagnostics had the fda on their heels, a failed and humiliating transaction w/GE (government electric) and a large drop in orders for their architect-line of automated analyzers. It’s not surprising that they punted the ball to inverness to develop this cutting edge technology. Abbott and inverness do not compete with each other in this space-a perfect marriage.

Moro’s lab (pacific bioscience) is a creditor. The non exclusive license to be grantee for failure to reimbursement moro’s lab by 2013 is reasonable language. There will be many granted non exclusive licenses by 2013. Having a non exclusive license does not control the intellectual property and royalty payments will still go to bocx.

The domain issues raised on this message board are bizarre and close to libelous. Just like the falsehoods about insider trading and large hedge positions by smithline—extremely little by both: look at the filings.

I’m excited. The corporate structure compliments the many facets of this technology. It appears that setting up oncopet diagnostics as a subsidiary enables a joint venture or possible spinoff.

I like the new executive team. They have a successful track record in diagnostics.

The science works. They are coming.

Sincerely yours,

Mr. mata